| |
 |
Samaritan Pharmaceuticals, Inc. (AMEX: LIV) |
 |
Dear Readers,
More good news from Samaritan Pharmaceuticals (AMEX: LIV) reached our desks this week as it announced encouraging preliminary results with its "Oral" Entry Inhibitor, now in Phase II trials. Please read the exciting news below.
We also encourage you to review our Full StockUpTicks Profile on Samaritan.
You may also wish to read some of our musings on stem cells here at our SmallCap Sentinel sister site.
|
*BREAKING* News From Samaritan |
|
Press Release
Source: Samaritan Pharmaceuticals Inc.
Tuesday May 30, 8:59 am ET
Samaritan Reports Positive Preliminary Results with ''Oral'' HIV Entry Inhibitor
in Phase II 10-Day HIV Monotherapy Trial
LAS VEGAS--(BUSINESS WIRE)--May 30, 2006--Samaritan Pharmaceuticals Inc. (AMEX:LIV - News):
- Data Shows 0.4 log10 Difference Between the High-Dose and the Placebo Control Group
- Dose dependent relationship in the number of subjects who had a reduction in viral load with the high dose group showing the most difference as compared to placebo (55% SP-01A vs. 0% placebo)
Samaritan Pharmaceuticals Inc. (AMEX:LIV - News) a developer of innovative drugs, announced today, its preliminary results showing antiviral activity in only 10 days with its Phase II 10-Day Monotherapy study where SP-01A, an oral entry inhibitor, was tested "alone" in patients experiencing HIV drug resistance.
The study, a Phase II double-blind, placebo controlled, multi-dose study in treatment-experience HIV patients, assessed SP01A's safety and effect on viral load in HIV-1 positive individuals, with evidence of increasing viral load, despite treatment with antiretroviral therapy.
In the preliminary finding, SP-01A was found to have a 0.4 log10 difference between the high dose group (800mg/day) and the placebo control group. In addition, there was a dose dependent relationship in the number of subjects who had a reduction in viral load with the high dose group (800mg/day) showing the most difference as compared to placebo (55% vs. 0%, respectively).
Dr. Greeson, CEO of Samaritan Pharmaceuticals stated, "Clinically SP-01A has always been tested in concert with other antiretroviral drugs, this is the first time it was tested alone. We are very encouraged with the results and look forward to developing SP-01A to hopefully be the first orally administered entry cell inhibitor drug with a 'firewall' mechanism of action." Dr. Greeson went on to say, "We started our Phase II 28-day monotherapy study and we are continuing to enroll patients. Hopefully, the second stage study will confirm the 10-day and possibly be more encouraging since we believe SP-01A takes a little time to work."
HIV 10-day Monotherapy Clinical Trial Highlights:
The study enrolled 32 evaluable patients in four SP-01A daily dose groups of placebo, 200mg, 400mg, and 800mg. Mean change in viral load for the placebo and active arms, as measured from baseline to Day 11, showed an increase of 0.4 log10 copies/ml for the placebo group, 0.1 log10 copies/ml for the 200mg/day dose group, 0.1 log10 copies/ml for the 400mg/day dose group, and no change for the 800mg/day copies/ml. The percentage of subjects having a reduction in viral load over the 10 day monotherapy treatment period were 0% for the Placebo group, 14% for the 200mg/day group, 25% for the 400mg/day group, and 55% for the 800mg/day group.
Samaritan Pharmaceuticals: "We LIV....to Save Lives."
Samaritan is a small-cap Biotech, driven to discover, develop and commercialize innovative therapeutics' for AIDS, Alzheimer's, Cancer and Heart disease patients. Look at www.samaritanpharma.com. Please register on Website so we can notify you of upcoming conference calls, news and events.
Disclaimer
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements.
Contact:
Samaritan Pharmaceuticals Inc., Las Vegas
Gene Boyle, 702-735-7001
GeneBoyle@SamaritanPharma.com
Source: Samaritan Pharmaceuticals Inc.
>>
|
About Samaritan |
|
Samaritan Pharmaceuticals, Inc. (AMEX:LIV) is a drug development company driven to discover, develop and commercialize new, innovative drugs for AIDS, Alzheimer’s, Cancer and Heart disease. Samaritan is currently advancing eight promising compounds out of its rich pipeline of 250 possible drug candidates, all of which have the potential to create revenue-generating opportunities. In addition, the majority of Samaritan’s patented drugs are credentialed with peer-reviewed journals and some with National Institutes of Health ( NIH) grants.
 aaaa
Drug Development
HIV Phase IIb/III Drug Program: Samaritan is currently developing SP-01A through PIIb/III pivotal clinical human trials for HIV drug resistant patients who are failing triple therapy.
Alzheimer's Drug Program: Samaritan has accomplished all the preclinical trials necessary to file for an IND for its Alzheimer's drug SP-233.
Samaritan Corporate
Samaritan’s business offices are located in Las Vegas, Nevada. The main business of the corporate office is drug development and business development; with research and discovery, taking place at Samaritan Laboratories, Georgetown University, Washington, D.C. Samaritan Corporate focuses on accomplishing the pre-clinicals required to file for Investigational New Drug applications, (IND's), Food and Drug Administration (FDA) Human Clinical Trials and everything necessary to get drug candidates regulatory approval. Its strategy is to partner most of its drug candidates with major pharmaceuticals, except for the ones that it can financially carry alone.
The Stars of Samaritan's Drug Candidate Pipeline
|
Recent News From Samaritan |
|
Press Release Source: Samaritan Pharmaceuticals, Inc.
Tuesday May 23, 9:22 am ET
Samaritan Files Provisional Patent to Support Promising New Type of
Anti-cholesterol Drug SP-1000 and Cover Additional Claims
Preclinical Animal Studies Found Cardiovascular Drug SP-1000 Reduces Blood Cholesterol
LAS VEGAS--(BUSINESS WIRE)--May 23, 2006--Samaritan Pharmaceuticals Inc. (AMEX:LIV - News):
* Clears Clogged Arteries
* Raises HDL
* Reduces CK Enzyme Marker: Suggesting It Improves, Hypercholesterolemia-Related Heart Suffering, Which Commonly Leads to Heart Attacks
Samaritan Pharmaceuticals Inc. (AMEX:LIV - News) a developer of innovative drugs, announced today, it has filed a new provisional U.S. patent application to support its original application, and add additional claims, for its cardiovascular drug SP-1000 for the prevention and treatment of cardiovascular disease.
Samaritan's collaborating scientists, through animal studies, validated SP-1000's ability to reduce blood cholesterol in animals. In addition, researchers validated SP-1000's ability, to clear clogged arteries of atheroma; raise HDL, the good cholesterol; and reduce CK enzyme elevations, a marker for heart suffering in animals.
Additionally, researchers have identified SP-1000 as having a new mechanism of action, i.e. it directly targets cholesterol in the blood and appears to be active at the lowest dose tested, which could suggest minimal side effects if tested in people.
To read the complete release and disclaimer, Click Here
Press Release Source: Samaritan Pharmaceuticals, Inc.
Tuesday May 2, 9:15 am ET
Samaritan Starts Enrolling for Its PII Stage 2 (28 Day Monotherapy)
Study of ''Oral'' Entry Inhibitor SP-01A
LAS VEGAS--(BUSINESS WIRE)--May 2, 2006--Samaritan Pharmaceuticals (AMEX:LIV - News):
* Completed Phase II Stage 1 (10 Day Monotherapy)
* Expect to Report Stage I Preliminary Results at Shareholders Meeting May 31st
* Expect Final PII Stage I Report July
* Currently Enrolling Phase II Stage 2
Samaritan Pharmaceuticals Inc. (AMEX:LIV - News) a developer of innovative drugs, announced today, it completed a Phase II Stage 1 (10 day monotherapy study) with 34 patients in which SP01A was being evaluated as an adjunct therapy for treatment-experienced HIV patients who are failing on their current anti-viral therapy. Samaritan also notes it has started enrolling for its Stage 2 (28 day monotherapy trial) and numerous Stage 1 evaluates are rolling over to Stage 2 which will count toward the 60 evaluates Samaritan intends to enroll for the Phase II Stage 2.
Dr. Janet Greeson, CEO of Samaritan stated, "Completing this 10 day HIV monotherapy study of SP01A is a significant milestone in its clinical development. We anticipate locking the data from this study at the end of this month and with a bit of luck will report preliminary results at the shareholders meeting, May 31, 2006. We expect to submit the (10 day monotherapy) final report to the FDA in July 2006. We remain resilient in advancing SP01A through FDA clinical trials hoping it might serve as a life-saving drug for HIV drug resistant patients."
To read the complete release and disclaimer, Click Here
Press Release Source: Samaritan Pharmaceuticals, Inc.
Thursday March 9, 8:00 am ET
UPDATE: Samaritan Kicks Off Follow-On HIV Study
LAS VEGAS--(BUSINESS WIRE)--March 9, 2006--Samaritan Pharmaceuticals Inc. (AMEX:LIV - News) a developer of innovative drugs, announced today, it is starting a second Phase II monotherapy trial, of its lead oral entry inhibitor anti-viral agent SP01A, in treatment experienced HIV-infected patients.
Dr. Thomas Lang, Samaritan's Chief Drug Development Officer stated, "We have completed enrollment for our first monotherapy trial and the start of this second trial means we have cleared another important milestone in SP01A's development path."
Dr. Janet Greeson, CEO of Samaritan stated, "We remain enthusiastically confident in the promise of SP01A. As we successful complete each of these FDA milestones, it completely strengthens our belief in SP01A as a life-saving drug for HIV drug resistant patients."
To read the complete release and disclaimer, Click Here
a
a
|
Financial Highlights For Samaritan |
|
a
Sector: Healthcare
Industry: Biotechnology
MEMBER
AMEX COMPOSITE INDEX (AMEX: ^XAX)
AMEX HEALTHCARE SUB INDEX (^XHL)
Last Trade: $0.41 (06-06-06)
Market Cap: $58.31M
52wk Range: $0.31 - $0.92
Fiscal Year Ends: 31-Dec
Most Recent Qtr : 30-Sep-05
Income Revenue (ttm): $135.43K
Total Cash (mrq): $1.60M
State of Incorporation: NV
|
Transfer Agent: Securities Transfer Corporation
|
a
To view the latest filings from LIV on the SEC Web site, Click Here
a
|
TO CONTACT SAMARITAN (AMEX: LIV) |
|
Samaritan Pharmaceuticals, Inc.
101 Convention Center Drive, Suite 310, Las Vegas, NV 89109
Phone: 702-735-7001 - Corporate Web Site: Click Here
Primary IR Contact: Kristi Eads
Phone: 702-735-7001 - Fax: 702-737-6016
E-mail: Click Here
*** The Bull is Running. ***
There may never be a better time to feature YOUR company
to over 1 MILLION investors.
To learn more about our programs email us directly at info@stockupticks.com
Stockupticks Safe Harbor Statement: Statements contained in this document, including those pertaining to estimates and related plans, potential mergers and acquisitions, estimates, growth, establishing new markets, expansion into new markets and related plans other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP). MP provides no assurance as to the subject company's plans or ability to effect any planned and/or proposed actions. MP has no first-hand knowledge of management and therefore cannot comment on its capabilities, intent, resources, nor experience and makes no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources believed by MP to be reliable, but MP provides no assurance, and none is given, as to the accuracy and completeness of this information.
Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP). The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. Past performance is no guarantee of future results. This report is a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision. MP has been paid forteen thousand two hundred fifty dollars by Samaritan Pharmaceuticals and will receive an additional forty-seven hundred fifty dollars for preparation and distribution of this report and other advertising services through June of this year. This constitutes a conflict of interest as to MP’s ability to remain objective in its communication regarding the subject company. Write or call MP for detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934 - Market Pathways 17595 Harvard Ave., Suite C519 Irvine, CA 92614. MP is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is a paid advertisement. Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results. The opinions contained herein reflect our current judgment and are subject to change without notice. MP and/or its affiliates, associates and employees from time to time may have either a long or short position in securities mentioned. Information contained herein may not be reproduced in whole or in part without the express written consent of Market Pathways Financial Relations Incorporated. |
|
